skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients

Expert Opinion

(1643) Views  (436) Full article downloads

Authors: Antonini A, Calandrella D

Published Date May 2011 Volume 2011:7(1) Pages 297 - 302
DOI: http://dx.doi.org/10.2147/NDT.S10097

Angelo Antonini¹, Daniela Calandrella²
¹Department for Parkinson’s Disease, IRCSS San Camillo, Venice, Italy; ²Department for Parkinson’s Disease, Clinic San Pio X, Milan, Italy

Abstract: Immediate-release (IR) pramipexole is indicated for the symptomatic treatment of idiopathic Parkinson’s disease (PD), either alone (without levodopa) or in combination with levodopa, that is, during the entire progress of disease up to the advanced stage. It is also currently indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS). An extended-release (ER) formulation of pramipexole has been developed to allow a once-daily formulation and to provide more stable dopaminergic stimulation. This review summarized the pharmacokinetic profile of pramipexole for both the IR and ER formulations, and discussed the role of pramipexole in the management of early and advanced PD. The introduction of a once-daily formulation of pramipexole poses significant potential advantages for patients and this is reflected by relatively stable plasma levels. The most obvious benefit is convenience of use and better adherence to treatment schedule. Additional advantages may be represented by the opportunity to provide continuous drug delivery in a fashion that could potentially help minimize dyskinesia risk if the drug is used early in the disease course.

Keywords: advanced Parkinson’s disease, continuous drug delivery, early Parkinson’s disease, extended release, immediate release, pramipexole





 

Other articles by Professor Angelo Antonini



Readers of this article also read: